Addex Therapeutics LTD 20-F annual reports
The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.
NASDAQ
Addex Therapeutics reports a net loss of CHF 6.7 million for 2025 while highlighting substantial doubt regarding its ability to continue as a going concern beyond mid-June 2026.
NASDAQ
Addex Therapeutics reports a net profit for 2024 driven by reduced operating losses and the divestment of its allosteric modulator drug discovery platform.
NASDAQ
Addex Therapeutics provides a detailed overview of its share capital structure, including shareholder distribution, capital bands, and conditional share capital as of February 29, 2024.